Clinical Trials
31 trialsHypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
ROADSTER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
RROPE
University of Utah
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
Barbara Ann Karmanos Cancer Institute
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
CCRO025
University of California, Davis
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Roswell Park Cancer Institute
FASTR-2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
InSightec
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Providence Health & Services
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Children's Oncology Group
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
Trans Tasman Radiation Oncology Group
IPI
Heidelberg University
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
Alliance for Clinical Trials in Oncology
Preoperative Radiation Therapy for High Risk Prostate Cancer
Duke University
Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer
Cairo University
Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)